title: Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
abstract: This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1-2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III-IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.
authors.affiliation: Centre Henri Becquerel, Rouen, France.
authors.forename: A
authors.initials: A
authors.lastname: Stamatoullas
authors.affiliation: Department of Hematology-Oncology, Hospital Saint Louis, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Brice
authors.affiliation: SFGM-TC, Paris, France.
authors.forename: M S
authors.initials: MS
authors.lastname: Gueye
authors.affiliation: Centre Henri Becquerel, Rouen, France.
authors.forename: S
authors.initials: S
authors.lastname: Mareschal
authors.affiliation: Department of Clinical Hematology, Nantes University Hospital, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Chevallier
authors.affiliation: Institut Paoli-Calmettes, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Department of Hematology, Hopital Pitie-Salpetriere, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Nguyenquoc
authors.affiliation: Hematology CHU Angers, Angers, France.
authors.forename: S
authors.initials: S
authors.lastname: Francois
authors.affiliation: CHU Dupuytren, Université Limoges, Limoges, France.
authors.forename: P
authors.initials: P
authors.lastname: Turlure
authors.affiliation: Hôpital Lapeyronie, Montpellier, France.
authors.forename: P
authors.initials: P
authors.lastname: Ceballos
authors.affiliation: Service d'Hématologie et Thérapie Cellulaire, CHRU de Tours, Tours, France.
authors.forename: H
authors.initials: H
authors.lastname: Monjanel
authors.affiliation: Division of Hematology, Institut Gustave Roussy, Villejuif, France.
authors.forename: J-H
authors.initials: JH
authors.lastname: Bourhis
authors.affiliation: Department of Hematology, Hôpital Augustin Morvan, Brest, France.
authors.forename: G
authors.initials: G
authors.lastname: Guillerm
authors.affiliation: Department of Clinical Hematology, Hôpital Saint-Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire, APHP, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Department of Onco-Hematology, Centre Léon Berard, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.affiliation: Department of Hematology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France.
authors.forename: J
authors.initials: J
authors.lastname: Cornillon
authors.affiliation: Lymphoid Malignancies Unit, Hôpital Henri Mondor and Université Paris, Creteil, France.
authors.forename: K
authors.initials: K
authors.lastname: Belhadj
authors.affiliation: Hôpital de Brabois, Vandoeuvre les Nancy, France.
authors.forename: C
authors.initials: C
authors.lastname: Bonmati
authors.affiliation: Department of Hematology, Hopital Haut-Leveque, Pessac, France.
authors.forename: M-S
authors.initials: MS
authors.lastname: Dilhuydy
authors.affiliation: Department of Hematology, University Hospital of Toulouse, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Huynh
authors.affiliation: CHRU Rennes, Rennes, France.
authors.forename: M
authors.initials: M
authors.lastname: Bernard
authors.affiliation: Department of Hematology, Dijon University Hospital, Dijon, France.
authors.forename: M-L
authors.initials: ML
authors.lastname: Chrétien
authors.affiliation: Department of Hematology-Bone Marrow Transplantation, Saint Louis Hospital, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Peffault de Latour
authors.affiliation: Centre Henri Becquerel, Rouen, France.
authors.forename: H
authors.initials: H
authors.lastname: Tilly
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods* / Q000401:mortality; D016019:Survival Analysis; D014182:Transplantation, Autologous